Fig. 1From: A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancerBiochemical recurrence-free survival rates by risk group. Biochemical recurrence-free survival rates for low- (green), intermediate- (red), and high-risk patients (black)Back to article page